• T M Tomasa Irriguible, J Sabater Riera, E Poch López de Briñas, J Fort Ros, M J Lloret Cora, J Roca Antònio, A Navas Pérez, P Ortiz Ballujera, L Servià Goixart, F J González de Molina Ortiz, C Rovira Anglès, M Rodríguez López, A Roglan Piqueras, and los investigadores del estudio REGISFRA.
• Servicio de Medicina Intensiva, Hospital Germans Trias i Pujol , España. Electronic address: teresatomasa@gmail.com.
• Med Intensiva. 2017 May 1; 41 (4): 216-226.

ObjectiveThe aim of the study is to ascertain the most relevant aspects of the current management of renal replacement therapy (RRT) in critically ill patients, and to analyze renal function recovery and mortality in patients undergoing RRT.MethodsA non-interventional three-month observational study was made in 2012, with a follow-up period of 90 days, in 21 centers in Catalonia (Spain). Demographic information, severity scores and clinical data were obtained, as well as RRT parameters.Inclusion Criteriapatients aged ≥ 16 years admitted to Intensive Care Units (ICUs) and subjected to RRT.ResultsA total of 261 critically ill patients were recruited, of which 35% had renal dysfunction prior to admission. The main reason for starting RRT was oliguria; the most widely used RRT modality was hemodiafiltration; and the median prescribed dose at baseline was 35mL/kg/h. The median time of RRT onset from ICU admission was one day. The mortality rate at 30 and 90 days was 46% and 54%, respectively, and was associated to greater severity scores and a later onset of RRT. At discharge, 85% of the survivors had recovered renal function.ConclusionsCurrent practice in RRT in Catalonia abides with the current clinical practice guidelines. Mortality related to RRT is associated to later onset of such therapy. The renal function recovery rate at hospital discharge was 85% among the patients subjected to RRT.Copyright © 2016 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.

41 keywords...

hide…